ABT-199 alone treatment resulted in temporal reduction of MLL-ALL cells in PB, but residual leukemic cells in the BM and spleen and didn't prolong survival of ALL-engrafted recipients (Fig. S4a–d). The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.